Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Tanja D. de Gruijl, Niels W.C.J. van de Donk, Paul W. H. I. Parren, Thilo Riedl, Rob C. Roovers, Annemiek Broyl, Roeland Lameris, Iris de Weerdt, Jurjen M. Ruben, Victoria Iglesias, Anton Ep Adang, Benjamin Winograd, Arnon P. Kater, Hans van Vliet
Publikováno v:
Blood. 138:2266-2266
Background. Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity, such as Vγ9Vδ2-T and type 1 natural killer T (NKT) cells, may combine high therapeutic efficacy with limited off-tumor tox
Autor:
Shahram Kordasti, Arjan A. van de Loosdrecht, Ghulam J. Mufti, Hetty J. Bontkes, Nathalie van Leeuwen-Kerkhoff, Theresia M. Westers, Tanja D. de Gruijl
Publikováno v:
Blood. 126:4109-4109
Introduction Immune response plays an important role in the pathogenesis and progression of myelodysplastic syndromes (MDS). It has been shown that a consistent immunological signature in MDS comprises an increase in Th17 cells in low risk MDS and an
Autor:
Iris de Weerdt, Roeland Lameris, Mark-David Levin, Ester B. M. Remmerswaal, Sanne H. Tonino, Hans J. van der Vliet, Ineke J. M. ten Berge, Tom Hofland, Tanja D. de Gruijl, Renée C.G. de Bruin, Sanne Terpstra, Arnon P. Kater
Publikováno v:
Blood. 126:2914-2914
Background: Although T cell immunotherapy is considered a promising therapeutic approach in B cell malignancies, autologous T cell based therapy proved to be far less effective in CLL than in more aggressive B cell malignancies. This has been attribu
Autor:
Willemijn van den Ancker, Jurjen M. Ruben, Theresia M. Westers, Tanja D. de Gruijl, Hetty J. Bontkes, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht
Publikováno v:
Blood. 116:3283-3283
Abstract 3283 Whereas in 80% of the patients suffering from acute myeloid leukemia (AML) complete remission is achieved, the 5-year survival rate is only 30% - 40% due to relapse of the disease. In order to increase overall survival of AML patients,
Autor:
Theresia M. Westers, Tanja D. de Gruijl, Ada M. Kruisbeek, Willemijn van den Ancker, Hetty J. Bontkes, Pepijn G.J.T.B. Wijnands, Sandra van Wetering, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht
Publikováno v:
Blood. 116:2193-2193
Abstract 2193 Introduction. Vaccination with acute myeloid leukemia derived dendritic cells (AML-DC) is a promising immunotherapeutic tool to prevent relapse of AML due to presence of residual AML cells. However, in the clinical setting AML-DC vaccin
Autor:
Tanja D. de Gruijl, Saskia J. A. M. Santegoets, Ilse Houtenbos, Arjan A. van der Loosdrecht, Rik J. Scheper, Sergey Kipriyanov, Quinten Waisfisz, Theresia M. Westers, Fedor Denkers, Gert J. Ossenkoppele
Publikováno v:
Blood. 108:3710-3710
Dendritic cell (DC)-based immunotherapy faces new challenges since efficacy of DC vaccines in clinical trials has been inconsistent. Strategies to improve immune responses induced by DC are currently being explored. We have recently shown the feasibi